
Contemporary simultaneous heart–kidney transplantation recipients (SHKT) experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients. buff.ly/32hQK1w

English
Pharmacotherapy
3.7K posts

@PharmacoJournal
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy is an official journal of @ACCP.






































